Skip to main content
Monthly Archives

November 2018

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting

Nine abstracts accepted, including two oral presentations HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited…

Read More